Menu Menu Menu
Nice Insight Research
Content Menu
Menu Menu Menu
To Top

Search By Topic

Contract Development and Manufacturing (CDMO)

440 Articles available
CDMO

Preparing for Hurricane Florence in Pharma

PAO-M09-18-NI-013
Workforce

Grant Will Fund Workforce Development Program for Biopharma Industry

PAO-M09-18-NI-001
Acquistion

Olon Acquires Manufacturing Facility in India

PR-M09-18-NI-075
Appointment

UPM Pharmaceuticals Appoints Dr. Chi-Chang Wung as Director of Analytical Development

PR-M08-18-NI-125
Vaccines

GSK Ships 2018-19 Seasonal Influenza Vaccines for US Market

PR-M08-18-NI-110
Biologics

Building a Biologics Business from the Ground Up

PAP-Q2-18-CL-008
Regulatory

China to Accelerate Review of 48 Foreign Drugs

PAO-M08-18-NI-013
Acquisition

Intertek Groups Expands Offerings with the Acquisition of Alchemy Systems

PAO-M08-18-NI-012
Parenterals

A Risk Analysis Approach to Producing Environmentally Sensitive Parenterals

PA0-M06-18-CL-007
Regulatory

Reducing Time to Market with Targeted Regulatory Affairs Support

PAO-06-18-CL-003
Clinical Data

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

PR-M06-18-NI-062
Cell and Gene Therapy

StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform

PR-M06-18-NI-054
FDA

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to advance medical product communications to support drug competition and value-based health care

PR-M06-18-NI-048
Commercial Supply

Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)

PR-M06-18-NI-047
Hot Melt Extrusion

Leveraging Hot Melt Extrusion for Solubility and Continuous Manufacturing

PAP-Q2-18-CL-007
Acquisition

Alcami to Become Industry Leading Platform CDMO Following Acquisition by Madison Dearborn Partners

PR-M06-18-NI-021
Acquisition

Avara Pharmaceutical Services Acquires Major Sterile Manufacturing Facility and Development Center in Canada

PR-M05-18-NI-121
Mergers & Acquisitions

Inside Mergers & Acquisitions

PAP-Q2-18-CL-001
Biologic Candidates

Addressing Development Challenges for Complex Biologic Drug Candidates

PAP-Q2-18-CL-004
Contract Manufacturing Needs

Meeting Biopharma Contract Manufacturing Needs with a Flexible  Global Network

PAP-Q2-18-CL-006
Multi-Product Facility Manufacturing

Using a Risk-Based Approach to Manufacturing in a Multi-Product Facility

PAP-Q2-18-CL-009
GMP

State-of-the-Art Biologics Manufacturing in an Unexpected Location

PAP-Q2-18-CL-010
Cell and Gene Therapy

Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing

PAP-Q2-18-CL-011
OSD Facility Design

Modern OSD Facility Design Considerations for Operational Efficiency and Regulatory Compliance

PAP-Q2-18-CL-012
Corporate Social Responsibility

Corporate Social Responsibility as a Driver for Improved Sustainability

PAP-Q2-18-CL-014
Oral Peptides

Scientific Expertise Facilitates Oral Peptide Product Development and Manufacturing

PAP-Q2-18-CL-017
Market Expansion

BioPharma CDMO Success Requires Technical Leadership and Problem-Solving Capabilities

PAP-Q2-18-CL-019
Drug Discovery

TEVA Hopes to Launch New Migraine Drug Immediately After PDUFA Date

PAO-M05-18-NI-020
Novel Medicine

WuXi Laboratory Testing Division: Propelling Innovation and Better Treatments for Patients

PAO-M05-18-CL-004
FDA

New WuXi STA Solid-Dose API Plant Gets Okay from US FDA

PAO-M05-18-NI-004
Announcement

Alcami St. Louis Facility to be Honored by Missouri House of Representatives and City of St. Louis

PR-M05-18-NI-032
Drug Development

Praxbind®, Specific Reversal Agent for Pradaxa®, Now Available in 3,200 Hospitals Nationwide

PR-M05-18-NI-034
Announcement

Sanofi Named to DiversityInc's Top 50 Companies for Diversity®

PR-M05-18-NI-031
Drug Discovery

Bactevo Enters Drug Discovery Agreement with Boehringer Ingelheim

PR-M05-18-NI-024
Patient Adherence

New Approach by Novo Nordisk Ties Pricing to Patient Behavior

PAO-M04-18-NI-017
Expanded Capacity

Avara Pharmaceutical Services Hold Groundbreaking at New Aiken Site

PR-M04-18-NI-86
Awards

WuXi Biologics Wins CMO Leadership Award from Life Science Leader Magazine

PR-M04-18-NI-73
Donation

Grifols Donates Over 25 million International Units of Blood Clotting Factor in 2017

PR-M04-18-NI-70
Approval

Fresenius Kabi Announces New Approval and Immediate Availability of Daptomycin for Injection

PR-M04-18-NI-58
Drug Delivery

Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual Meeting

PR-M04-18-NI-55
CDMO

European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

PR-M04-18-NI-021
Expanded Capacity

AGC Biologics Increases Footprint in Bothell, WA

PR-M04-18-NI-016
Probiotics

J&J Involved in Probiotics Development Program

PR-M03-18-NI-100
Operational Excellence

Transforming A CDMO Using an Operational Excellence Approach

PAO-M03-18-CL-003
Award

Piramal Pharma Solutions Wins in Six Categories at the 'CMO Leadership Awards 2018'

PR-M03-18-NI-099
Drug Development

More Good News for Novo Nordisk’s Semaglutide and Weight Loss

PAO-M03-18-NI-024
Production

LANXESS Starts Production Line for Specialty Compounds in Germany

PAO-M03-18-NI-022
Influenza

Anti-Flu Drug Exploits Weakness in H3N2 Strain

PAO-M03-18-NI-021
Oncology

Tumor Derived T cells Demonstrate Potential Against Ovarian Cancer

PAO-M03-18-NI-020
Expanded Capacity

Hovione Reports on Recent Capacity Expansion and Future Plans to Support Growth

PR-M03-18-NI-081
DCAT

DSM Sinochem Pharmaceuticals hosts second “public-private dialogue on combating Antimicrobial Resistance” during DCAT week

PR-M03-18-NI-072
Donation

Alcami Donation to Outfit TROSA Medical Department

PR-M03-18-NI-065
Acquistion

Siegfried Purchases the Drug Product Manufacturing Facility of Arena Pharmaceuticals GmbH in Zofingen

PR-M03-18-NI-058
Approval

European Commission Expands Marketing Approval for GSK’s Relvar Ellipta

PAO-M03-18-NI-013
Cell Line

Abzena Strengthens Specialized Bioassay Offering Through Access Agreement with Major Cell Line Depository

PR-M03-18-NI-053
M&A Activity

M&A Activity in a Fragmented CDMO Market

PAP-Q1-18-NI-001
Serialization

Facilitating Implementation and Customer Service with Offline Serialization

PAP-Q1-18-CL-005
Strategic Collaboration

Driving Change in the Pharma Industry and Biotech One Relationship at a Time

PAP-Q1-18-CL-004
Industry

Why Business Continuity Management is Important for CDMOs

PAP-Q1-18-CL-003
Fill/Finish

Getting to the Finish Line

PAP-Q1-18-NI-004
Sponsor

What’s Driving M&A Among Pharma Sponsors?

PAP-Q1-18-NI-003
Capsules

Overcoming Formulation Challenges with Liquid-fill Capsules

PAP-Q1-18-CL-004
Pharmageddon

Uniting the Industry for the Prevention of “Pharmageddon”

PAP-Q1-18-CL-001
Formulation

Investing in New Technologies for Innovative Functional Solutions

PAP-Q1-18-CL-009
Injectables

Meet Chemo CMO: Preferred Partner for Injectables Manufacturing

PAP-Q1-18-CL-015
Biologics

Fully Supporting Customer Needs for Biologics Development and Manufacturing

PAP-Q1-18-CL-016
API Manufacturing

Meeting the Need for Small-Volume API Manufacturing

PAP-Q1-18-CL-016
Fermentation

Focused on Fermentation

PAP-Q1-18-CL-007
Business

DSM Sinochem Pharmaceuticals Is for Sale

PAO-M03-18-NI-009
Expanded Capacity

Catalent Completes $4.6 Million Expansion at Singapore Clinical Supply Facility

PR-M03-18-NI-008
License Agreement

Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates

PR-M03-18-NI-009
Innovation

Thermo Fisher Supplies Analytical Instruments to World Anti-Doping Agency Laboratory in South Korea

PR-M03-18-NI-011
Facility

First Order Reported for New Samsung Plant

PAO-M03-18-NI-001
Drug Delivery

Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta® (pegfilgrastim)

PR-M03-18-NI-002
Innovation

Thermo Fisher Scientific Innovations Offer Greater Connectivity and Ease of Use

PR-M03-18-NI-005
Cell and Gene Therapy

Brammer Bio Supports Rare Disease Day 2018

PR-M03-18-NI-006
FDA

WuXi Biologics Congratulates MabSpace on FDA Clearance of IND for MSB2311

PR-M03-18-NI-001
NDA

FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

PR-M02-18-NI-108
FDA Acceptance

Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing

PR-M02-18-NI-106
Expanded Capacity

LANXESS expands capacity for Macrolex dyes at its Leverkusen site

PR-M02-18-NI-104
Agreement

Abarca, Amgen Enter Outcomes-Based Agreement For Repatha® (evolocumab)

PR-M02-18-NI-103
Expanded Capacity

CapsCanada Expands K-CAPS®(HPMC Capsules) Manufacturing Capacity for Second Time

PR-M02-18-NI-109
CDMO

Servier Reports Year-On-Year Growth

PAO-M02-18-NI-024
Drug Development

HEPAXA is a New Treatment in the US from BASF for Patients with NAFLD

PAO-M02-18-NI-023
Drug Development

Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe

PR-M02-18-NI-102
Innovation

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer

PR-M02-18-NI-100
Clinical Data

Bayer Announces Publication of Larotrectinib Data in The New England Journal of Medicine

PR-M02-18-NI-97
Vaccine

AstraZeneca Announces Renewed Recommendation and Availability of FLUMIST QUADRIVALENT Vaccine in the US

PR-M02-18-NI-96
Analytical Services

AMRI to Expand Container Closure Integrity Testing Services (CCIT) into European Union

PR-M02-18-NI-94
Combination Treatment

Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program

PR-M02-18-NI-92
Drug Development

Kidney Disease Drug Licensed to AstraZeneca

PAO-M02-18-NI-022
Robotics

Johnson & Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics

PR-M02-18-NI-91
Generics

Perrigo Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%

PR-M02-18-NI-90
Clinical Trials

Aimmune’s AR101 Meets Phase 3 Endpoints

PAO-M02-18-NI-020
Appointment

Catalent Announces Changes to its Board of Directors

PR-M02-18-NI-84
Clinical Trials

AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks

PR-M02-18-NI-83
Drug Development

Evotec and MaRS Innovation Announce First Funded Project under LAB150 Bridge

PR-M02-18-NI-79
Clinical Trials

Breakthrough Scar Treatment in Clinical Trials

PAO-M02-18-NI-016
Strategic Collaboration

Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214

PR-M02-18-NI-73
Approval

Celltrion Receives EU Approval for Trastuzumab Biosimilar

PR-M02-18-NI-71
Cell Culture Portfolio

Lonza Expands Cell-Culture Portfolio with Quasi Vivo ® System

PR-M02-18-NI-59
SCRS' Global Impact Partner Program

Boehringer Ingelheim Demonstrates their Commitment to Site Relationships by Joining SCRS' Global Impact Partner Program

PR-M02-18-NI-56
Dermatology

Sun Pharma Announces Twelve Tildrakizumab Abstracts to be Presented at American Academy of Dermatology 2018 Annual Meeting

PR-M02-18-NI-54
Strategic Collaboration

Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb

PR-M02-18-NI-55
Inhalation

Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol

PR-M02-18-NI-53
Growth

Fueled by Growth, Alcami Unveils New Sales Office in Cambridge, MA

PR-M02-18-NI-63
Strategic Partnership

ImmunoQure AG and Servier Enter into Strategic Partnership for the Development of an Interferon-alpha Human Autoantibody

PR-M02-18-NI-64
Acquistion

LANXESS successfully completes acquisition of Solvay’s phosphorus additive business

PR-M02-18-NI-051
Generics

Teva Announces Launch of a Generic Version of Syprine® in the United States

PR-M02-18-NI-050
FDA Approval

Pii and Its Partners Received FDA Market Approval for Seven Products and Commercially Launched 6 Products in 2017

PR-M02-18-NI-048
Strategic Partnership

Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines

PR-M02-18-NI-047
Acquistion

Allergen Acquires Elastagen

PAO-M02-18-NI-012
Launch

WuXi AppTec Launches Advanced Library Compound Initiative on LabNetwork.com

PR-M02-18-NI-039
Award

Thermo Fisher Scientific Wins CiteAb 2018 Award for its Antibody Validation Initiative

PR-M02-18-NI-040
Strategic Partnership

AbbVie and MBC BioLabs Team Up to Support Life-Science Startups in the San Francisco Bay Area

PR-M02-18-NI-037
Clinical Trials

Tyzivumab is Ready for Trials

PAO-M02-18-NI-011
Biomanufacturing

Amgen to Open Biomanufacturing Plant in the US

PAO-M02-18-NI-010
FDA Approval

Grifols HyperRAB® (rabies immune globulin [human]) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection

PR-M02-18-NI-036
Packaging

SCHOTT AG, ARaymondlife and Vanrx Pharmasystems announce product compatibility for primary packaging of sterile injectables

PR-M02-18-NI-035
Research

Lonza to Present Latest Research into More Physiologically Relevant ADME-Tox Models at the Society of Toxicology Meeting

PR-M02-18-NI-034
Marketing

Evonik Launches a New MetAMINO® Marketing Campaign to the Middle East and African Markets At VIV MEA in Abu Dhabi

PR-M02-18-NI-033
Launch

Thermo Fisher Scientific Launches Axiom Microbiome Array for Research

PR-M02-18-NI-032
Acquistion

Celanese Completes Omni Acquisition

PAO-M02-18-NI-009
Investment

Polpharma Group Gets Digital

PAO-M02-18-NI-008
CDMO

Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO

PR-M02-18-NI-030
Acquistion

Celgene Corporation Commences Tender Offer for Juno Therapeutics, Inc.

PR-M02-18-NI-026
Generic

Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® Tablets

PR-M02-18-NI-025
Appointment

PPD Names Maria Teresa Hilado, CFO of Allergan, to its Board of Directors

PR-M02-18-NI-023
Joint Venture

DSM and Evonik Establish Veramaris Joint Venture

PR-M02-18-NI-024
Acquistion

Partner Therapeutics (PTx) Acquires Leukine® from Sanofi

PR-M02-18-NI-021
Investment

Dracen Pharmaceuticals Raises Over $40 million

PAO-M02-18-NI-007
Drug Development

Mylan and Theravance Will Receive FDA Decision on COPD Drug by November

PAO-M02-18-NI-006
Immuno-Oncology

Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

PR-M02-18-NI-020
Clinical Trials

Novartis Announces NEJM Publication Of Updated Analysis From ELIANA Trial Showing Longer-Term Durable Remissions With Kymriah™ In Children, Young Adults With r/r ALL

PR-M02-18-NI-019
CEO

Rentschler Biopharma SE Appoints International Biopharma Expert Dr. Ralf Otto as Chief Operating Officer

PR-M02-18-NI-018
Investment

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

PR-M02-18-NI-017
Leadership

Avara Pharmaceutical Services Wins CMO Leadership Awards in All 6 Categories for Contract Manufacturing

PR-M02-18-NI-016
Expanded Capacity

Cambrex Expands Process Research and Development Capabilities Across North America

PR-M02-18-NI-014
IND Application

WuXi Biologics Congratulates BioAtla on FDA Clearance of IND Application for CAB-AXL-ADC

PR-M02-18-NI-011
Healthcare

Leading Companies Taking Action to Address Healthcare

PAO-M02-18-NI-005
×